News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

European Medicines Agency Approves Once Every Two Weeks Dosing Option For CSL Behring UK Ltd's Hizentra® (Human Normal Immunoglobulin, SCIg)


12/5/2013 8:07:34 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HAYWARDS HEATH, England--(BUSINESS WIRE)--CSL Behring UK Ltd announced today that the European Medicines Agency (EMA) has expanded the administration options for Hizentra®?, human normal immunoglobulin, SCIg, 20% liquid, to include dosing once every two weeks (fortnightly).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES